Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Researchers find novel gene driving fat cell development and metabolic disorders.Thursday 07 December 2017
In a recent study published in The American Journal of Pathology researchers found a novel gene, ADAMTS18 that impacts body fat percentage and fat cell size. Mice that are lacking the gene also showed early metabolic syndrome including hyperlipidem ...
Blog - 6 'must haves' to get life science researchers using big data analyticsThursday 26 October 2017
This blog is a summary of the presentation by Arie Baak of Euretos that will be held at the Global Pharma R&D Informatics conference on the 1st of December in Lisbon. The main topic is how the Euretos AI platform enables researchers, most of wh ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.